NONMEM Users Network Archive

Hosted by Cognigen

RE: Weight based dosing

From: Rudy Gunawan <RGunawan>
Date: Wed, 9 Dec 2015 01:10:00 +0000

Hi Abdullah Sultan,

Since your estimate is not too far from 0.75 exponent in Clearances, did yo=
u try using the theoretical allometric scaling (0.75 in all clearances and =
1.00 in volumes)? With these, it would be easier to justify. Once you inclu=
de the body size, I would suggest you check the matrix plots of ETA in CL o=
r V versus other covariates (demo, labs, etc) to see if there is any other =
info would help explain the variability. Without knowing more of the nature=
 of the drug, I think these would help build the model.

Hope this helps,


From: owner-nmusers
 Behalf Of Sultan,Abdullah S
Sent: Tuesday, December 08, 2015 4:40 PM
To: nmusers
Subject: [NMusers] Weight based dosing

Hi everyone,

I am developing a POP PK model for an anti-infective drug, I am trying to d=
etermine if dosing should be weight based or not. The range of weight in th=
e study was 40-100 kg.

Weight was statistically significant for Cl/F but only explained 9% of the =
variability observed for Cl.

I used allometric scaling to describe weights effect on Cl/F and slope effe=
ct of weight was 0.58, and scaled to 60 kg (the median).

Based on the slope effect estimated, AUC is predicted to decrease by 15% fo=
r an 80 kg individual, and increase by 25% for an individual that weights 4=
0 kg compared to a 60 kg individual.

How much should I trust the slope effect determined by my study? and should=
 I rely on it to develop the dosing regimen?

if weight only explained 9% of variability observed with Cl/F, could that i=
ndicate that it is not clinically significant and weight based dosing is no=
t required?


Abdullah Sultan, PhD candidate

University of Florida

Received on Tue Dec 08 2015 - 20:10:00 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: